Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 16500927.
- Also identified by PMC identifier 1432198.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate whether using ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is preceded by symptoms of behavioural and emotional problems in childhood and early adolescence. Prospective, longitudinal, population based study The Dutch province of Zuid-Holland. A sample of 1580 individuals, followed up across a 14 year period, from childhood into adulthood. The first assessment took place in 1983 before MDMA appeared as a recreational drug in the Netherlands and included the child behaviour checklist to obtain standardised parents' reports of their children's behavioural and emotional problems. Use of the drug was assessed with the composite international diagnostic interview 14 years later. Eight syndrome scales of childhood behaviour were examined. Scores in the deviant range for the scales designated as anxious or depressed in childhood were significantly related to use of MDMA in adolescents and adults, resulting in an increased risk (hazard ratio 2.22, 95% confidence interval 1.20 to 4.11, P = 0.01). Individuals with childhood symptoms of anxiety and depression may have an increased tendency to use MDMA in adolescence or young adulthood. Its effects are supposed to include enhanced feelings of bonding with other people, euphoria, or relaxation. Especially individuals with symptoms of anxiety or depression may be susceptible to these positive effects.
Medical subject headings
- Anxiety Disorders
- Depressive Disorder
- Hallucinogens
- N-Methyl-3,4-methylenedioxyamphetamine
- Substance-Related Disorders